Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy
- PMID: 29981025
- DOI: 10.1245/s10434-018-6608-1
Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy
Abstract
Background: Breast cancer subtype, as determined by the expression of estrogen receptor (ER) and progesterone receptor (PR), together defined as hormone receptor (HR) status, and the HER2/neu receptor (HER2), is important in predicting prognosis and guiding therapy. Knowledge regarding how tumors evolve during treatment and whether subtype is influenced by neoadjuvant chemotherapy (nCT) is limited. The purpose of this study was to compare the HR and HER2 status between core needle biopsy and residual tumor after surgery of breast cancer patients treated with nCT and to evaluate the impact of status change on therapeutic management.
Methods: After institutional review board approval, we performed a retrospective review of all patients with a diagnosis of breast cancer who received nCT and had their initial biopsy and post-nCT surgical specimens evaluated for tumor subtype between January 2009 and December 2014 at our institution. Immunohistochemistry (IHC) of ER, PR, HER2, and fluorescence in situ hybridization for HER2 expression, when indicated, was performed using identical technique and measured by a single pathologist who specializes in breast pathology. Pre- and post-nCT subtype was cross-tabulated to assess change. Standard diagnostic metrics were computed.
Results: Fifty-two patients with 54 cancers were identified to have their initial biopsy and post-nCT surgical specimens evaluated for tumor subtype in identical fashion. There was a complete pathologic response after nCT in 23 cancers (42.6%). Residual disease was noted in 31 cancers (57.4%). Five of these (16.1%) had a change in tumor subtype, of which four changes were based on IHC. HR status changed from positive to negative in two cases and from negative to positive in one case. HER2 status changed from positive to negative in one case and from negative to positive in one case. Subtype change led to treatment change in all five cases, with either the addition or discontinuation of adjuvant therapies.
Conclusions: Patients with breast cancer may experience alterations in their tumor subtype after nCT. At our institution, this led to a change in adjuvant treatment in 100% of such patients. This implies that retesting receptor status of residual tumors after nCT should be routinely performed to tailor adjuvant therapy after nCT.
Similar articles
-
Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.Int J Clin Exp Pathol. 2012;5(6):530-6. Epub 2012 Jul 29. Int J Clin Exp Pathol. 2012. PMID: 22949935 Free PMC article.
-
Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.Clin Breast Cancer. 2013 Feb;13(1):53-60. doi: 10.1016/j.clbc.2012.09.011. Epub 2012 Oct 26. Clin Breast Cancer. 2013. PMID: 23103368
-
Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx® for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy.Ann Surg Oncol. 2019 Oct;26(10):3232-3239. doi: 10.1245/s10434-019-07555-w. Epub 2019 Jul 24. Ann Surg Oncol. 2019. PMID: 31342379
-
Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.Eur J Surg Oncol. 2017 Apr;43(4):642-648. doi: 10.1016/j.ejso.2016.10.025. Epub 2016 Nov 17. Eur J Surg Oncol. 2017. PMID: 27889196 Review.
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21. Cancer Treat Rev. 2011. PMID: 21177040 Review.
Cited by
-
Irreversible inhibition of estrogen receptor α signaling and the emergence of hormonal resistance in MCF7 breast cancer cells induced by DNA damage agents.Biomed Rep. 2024 Jan 19;20(3):42. doi: 10.3892/br.2024.1727. eCollection 2024 Mar. Biomed Rep. 2024. PMID: 38343657 Free PMC article.
-
Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients.Int J Mol Sci. 2023 Sep 19;24(18):14254. doi: 10.3390/ijms241814254. Int J Mol Sci. 2023. PMID: 37762557 Free PMC article.
-
AI-Enhanced PET and MR Imaging for Patients with Breast Cancer.PET Clin. 2023 Oct;18(4):567-575. doi: 10.1016/j.cpet.2023.05.002. Epub 2023 Jun 17. PET Clin. 2023. PMID: 37336693 Free PMC article. Review.
-
Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy.Breast Cancer Res Treat. 2023 Jul;200(2):247-256. doi: 10.1007/s10549-023-06978-0. Epub 2023 May 26. Breast Cancer Res Treat. 2023. PMID: 37233961 Free PMC article.
-
HER2 changes to positive after neoadjuvant chemotherapy in breast cancer: A case report and literature review.World J Clin Cases. 2022 Jan 7;10(1):260-267. doi: 10.12998/wjcc.v10.i1.260. World J Clin Cases. 2022. PMID: 35071526 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous